Merck KGaA acquires cell culture media specialist Biochrom

22 August 2012

Germany’s Merck KGaA (MRK: DE) announced yesterday that it has entered into definitive agreements to acquire Biochrom AG located in Berlin, Germany. Financial terms of the transaction are not being disclosed.

Biochrom, with around 60 employees and sales of about 13 million euros ($16.9 million) in 2011, specializes in the production and marketing of cell-culture media and buffer solutions. The acquisition, which is subject to customary closing conditions such as the approval of the respective antitrust authority is expected to close in the fourth quarter of 2012.

Will strengthen Millipore business

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK